In breast cancer, 28%–47% of hormone receptor positive tumors and 23%–33% of HER2 positive tumors express mutations in PIK3CA, whereas the loss of PTEN is seen in 29%–44% of hormone receptor positive tumors and 22% of HER2 positive tumors [50]. Here, NR4A1 is linked to breast cancer.